209 related articles for article (PubMed ID: 36479670)
1. Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia.
Tantawy AAG; Elsherif NHK; Ebeid FS; El-Gamal RAE; Ismail EAR; Kenny MA; Morcos MBE
J Thromb Thrombolysis; 2023 Feb; 55(2):243-251. PubMed ID: 36479670
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura.
Chiou TJ; Chang YF; Wang MC; Kao CW; Lin HY; Chen TY; Hsueh EJ; Lan YJ; Sung YC; Lin SF; Bai LY; Chen CG
Transl Res; 2015 Dec; 166(6):750-761.e4. PubMed ID: 26477577
[TBL] [Abstract][Full Text] [Related]
3. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Tarantino MD; Fogarty PF; Shah P; Brainsky A
Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice.
Cheng X; Fu L; Ma J; Gu H; Chen Z; Zhao L; Wang X; Wu R
Blood Adv; 2021 Oct; 5(19):3799-3806. PubMed ID: 34605871
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment-a prospective cohort study.
van Dijk WEM; Poolen GC; Huisman A; Koene HR; Fijnheer R; Thielen N; van Bladel ER; van Galen KPM; Schutgens REG; Urbanus RT
J Thromb Haemost; 2023 Apr; 21(4):1020-1031. PubMed ID: 36696209
[TBL] [Abstract][Full Text] [Related]
6. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
[TBL] [Abstract][Full Text] [Related]
7. Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura.
Gardiner EE; Al-Tamimi M; Mu FT; Karunakaran D; Thom JY; Moroi M; Andrews RK; Berndt MC; Baker RI
J Thromb Haemost; 2008 Jul; 6(7):1175-82. PubMed ID: 18485087
[TBL] [Abstract][Full Text] [Related]
8. Study of a humanized inhibitory anti-platelet glycoprotein VI phage antibody from a phage antibody library.
Liu Q; Zhang C; Yu L; Shi Y; Zhang L; Peng J; Ji X; Hou M
Hematology; 2016 Jan; 21(1):60-7. PubMed ID: 26330203
[TBL] [Abstract][Full Text] [Related]
9. A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience.
Çekdemir D; Güvenç S; Özdemirkıran F; Eser A; Toptaş T; Özkocaman V; Haydaroğlu Şahin H; Ermiş Turak E; Esen R; Cömert M; Sadri S; Aslaner M; Uncu Ulu B; Karakuş A; Selim Bapur D; Alacacıoğlu İ; Aydın D; Tekinalp A; Namdaroğlu S; Ceran F; Tarkun P; Kiper D; Çetiner M; Yenerel M; Demir AM; Yılmaz G; Terzi H; Atilla E; Malkan ÜY; Acar K; Öztürk E; Tombak A; Sunu C; Salim O; Alayvaz N; Sayan Ö; Ozan Ü; Ayer M; Gökgöz Z; Andıç N; Kızılkılıç E; Noyan F; Özen M; Pepedil Tanrıkulu F; Alanoğlu G; Özkan HA; Aslan V; Çetin G; Akyol Erikçi A; Deveci B; Ersoy Dursun F; Dermenci H; Aytan P; Gündüz M; Karakuş V; Özlü C; Demircioğlu S; Akay Yanar OM; Özatlı D; Ündar L; Tiftik EN; Türköz Sucak AG; Haznedaroğlu İ; Özcan M; Şencan M; Tombuloğlu M; Özet G; Bilgir O; Turgut B; Özcan MA; Payzın KB; Sönmez M; Ayyıldız O; Dal MS; Ertop Ş; Turgut M; Soysal T; Kaya E; Ünal A; Pehlivan M; Atagündüz I; Tuğlular Fıratlı T; Saydam G; Diz Küçükkaya R
Turk J Haematol; 2019 Nov; 36(4):230-237. PubMed ID: 31327186
[TBL] [Abstract][Full Text] [Related]
10. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
Gao Y; Gong M; Zhang C; Kong X; Ma Y
Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
[TBL] [Abstract][Full Text] [Related]
11. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.
Khelif A; Saleh MN; Salama A; Portella MDSO; Duh MS; Ivanova J; Grotzinger K; Roy AN; Bussel JB
Am J Hematol; 2019 Feb; 94(2):200-208. PubMed ID: 30417939
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
14. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia.
Yang R; Li J; Jin J; Huang M; Yu Z; Xu X; Zhang X; Hou M
Br J Haematol; 2017 Jan; 176(1):101-110. PubMed ID: 27734464
[TBL] [Abstract][Full Text] [Related]
15. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
Yang F; Zong H; Li F; Luo S; Zhang X; Xu Y; Zhang X
Platelets; 2023 Dec; 34(1):2135694. PubMed ID: 36281771
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
18. [Eltrombopag for the treatment of primary immune thrombocytopenia in 23 pediatric patients].
Huang YT; Liu XF; Chen YF; Fu RF; Liu W; Xue F; Zhang L; Yang RC
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1031-1034. PubMed ID: 32023736
[No Abstract] [Full Text] [Related]
19. Eltrombopag in pediatric chronic and refractory ITP: data from a retrospective multicenter study from Lebanon.
Noun P; Inati A; Raffoul R; Younes JA; Mardini J; Khalife H
Ann Hematol; 2022 May; 101(5):991-997. PubMed ID: 35278100
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
Burness CB; Keating GM; Garnock-Jones KP
Drugs; 2016 May; 76(8):869-78. PubMed ID: 27151255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
